A Phase 3 clinical trial evaluating the additive value of PSMA PET for prostate cancer diagnosis in men with negative or equivocal MRI results reached primary completion on 2025-12-15, having enrolled 660 participants.
Background
Prostate cancer is a common malignancy, and accurate diagnosis is crucial for effective treatment planning. Magnetic Resonance Imaging (MRI) is a standard tool in prostate cancer detection, but its results can sometimes be negative or equivocal, leaving uncertainty for clinicians and patients. In such cases, additional diagnostic methods are needed to confirm or rule out significant prostate cancer. This trial investigates the potential of PSMA PET imaging to provide additive diagnostic value in these challenging scenarios, aiming to improve diagnostic precision where MRI alone is insufficient.
Trial design
This Phase 3 clinical trial, which has completed its primary data collection, enrolled 660 participants with Prostate Cancer. The study's objective was to evaluate the additive value of PSMA PET imaging for the diagnosis of significant prostate cancer (sPCa) in men who had previously received negative or equivocal results from an MRI scan.
What this means
The primary completion of this Phase 3 trial signifies that all planned data collection for the main objectives has concluded. While specific results are not yet available, the completion of this stage is a critical milestone for the study. Future analysis of the collected data will determine the diagnostic utility of PSMA PET in men with inconclusive MRI findings for prostate cancer, potentially informing future clinical guidelines for improved patient management.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT05154162, titled 'PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI', was recorded on 2025-12-15 on clinicaltrials.gov.